危及生命的癌症骨转移,救命的唑来膦酸怎么正确使用？

Osteoporosis is more common in postmenopausal women and the elderly. Symptoms such as joint pain and limited movement usually occur, and patients are prone to fractures of varying degrees. Zoledronic acid is commonly used in the treatment of osteoporosis, as it prevents mevalonate from maintaining a smooth metabolic pathway in cells and significantly inhibits the massive synthesis of cholesterol and prenoid lipids, thereby promoting osteoclast apoptosis. Moreover, it can prevent osteoclasts from absorbing large amounts of cartilage and immature bone tissue, effectively relieve pain, and has a significant therapeutic effect on osteoporosis. So, how to use the life-saving zoledronic acid correctly in life-threatening cancer bone metastasis?

Zoledronic acid should be administered intravenously. For adults, 4 mg each time should be diluted with 100 ml of 0.9% sodium chloride injection or 5% glucose injection and then infused intravenously. The infusion time should be no less than 15 minutes. Administer every 3-4 weeks or as directed by your doctor.

Zoledronic acid is a third-generation bisphosphonate drug. Its clinical indications include malignant hypercalcemia, postmenopausal osteoporosis, malignant tumor bone metastasis, etc. Studies have confirmed that zoledronic acid has a high affinity for the mineralized surface of bone, especially the active parts of bone turnover, and many drugs can maintain a certain blood concentration after sustained release. Zoledronic acid is currently the most pharmacologically active bisphosphonate drug. Compared with similar drugs, it has a stronger ability to bind hydroxyapatite, and zoledronic acid is more convenient to use. However, it has potential anti-angiogenic effects and can reduce the blood supply to the damaged site. Therefore, whether the use of zoledronic acid will reduce the blood supply to the fracture site and thereby affect fracture healing is one of the clinical controversies. However, some studies have reported that zoledronic acid does not affect the fusion rate of spinal bone grafting and does not cause delayed healing or nonunion of fractures.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.